In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Antonio Palumbo, MD
Advertisement
Articles by Antonio Palumbo, MD
Advertisement
Latest Updated Articles
New Standard of Care in Relapsed, Refractory Myeloma?June 6th 2016
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
The Intersection of Technology and Psycho-Oncology Care
5